[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100561437":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":22,"centralContacts":29,"locations":35,"responsibleParty":48,"collaborators":22,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":22,"eligibilityCriteria":58,"healthyVolunteers":54,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":22,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":22,"overallStatus":71,"whyStopped":22,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Assiut University","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"to delineate the role of erythropoietin in improving neonatal hypoxic ischemic encephalopathy","EXPERIMENTAL","Erythropoietin was administered in the first weeks of life at different multiple doses between 259-1000 UI\u002FKG\u002FD for 3 days",[13],"Drug: Erythropoietin",{"label":15,"type":6,"description":16,"interventionNames":17},"Role of Erythropoietin in neonate hypoxic ishemic encephalopathy","EPO reduces the need for blood transfusions in premature infants. To cross the blood-brain barrier",[13],{"label":19,"type":20,"description":21,"interventionNames":22},"Role of Erythropoietin in neonatal hypoxic ischemic encephalopathy","NO_INTERVENTION","prevent apoptosis of erythroid progenitor cells and to enhance their maturation and proliferation",null,[24],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":22},"DRUG","Erythropoietin","the role of erythropoietin in improving neonatal hypoxic ischemic encephalopathy",[15,9],[30],{"name":31,"role":32,"phone":33,"phoneExt":22,"email":34},"Shimaa fahmy, residant","CONTACT","01001483064","Shimaasaberfahmy1197@gmail.com",[36],{"facility":37,"status":22,"city":38,"state":22,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":22},"Assiut university children hospital","Asyut","71511","Egypt","EG",{"type":43,"coordinates":44},"Point",[45,46],31.18368,27.18096,{"lat":46,"lon":45},{"type":49,"investigatorFullName":50,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":22,"oldOrganization":22},"PRINCIPAL_INVESTIGATOR","Shimaa Saber Fahmy","resident doctor at internal medicine department","100561437","early-phase-1-erythropoietin-in-hie-neonate-100561437",false,"NCT06590155","Erythropoietin in HIE Neonate","Role of Erythropoietin in Neonates With Hypoxic Ischemic Encephalopathy","Inclusion Criteria:\n\n\\- neonates who less than 1 month suffer from hypoxic ischemic encephalopathy\n\nExclusion Criteria:\n\n* neonates who more than 1 month\n* neonates who suffer from brain insults other than HIE","ALL","1 Day","1 Month",{"count":63,"type":64},3,"ESTIMATED","INTERVENTIONAL",[67],"EARLY_PHASE1","this study is aim to delineate the role of erythropoietin in improving neonatal hypoxic ischemic encephalopathy the study is conducted to answer the question : is erythropoietin will improve neonatal hypoxic ischemic encephalopathy?",[70],"Neonatal Hypoxic Ischemic Encephalopathy","NOT_YET_RECRUITING","2024-09-06",{"date":74,"type":75},"2024-09-19","ACTUAL",{"date":77,"type":64},"2024-11-24",{"date":79,"type":64},"2029-02-24",{"name":5,"class":6},1]